Connect with us

Industry News

Greenlane Announces Financial Results for the Second Quarter of 2019

Avatar

Published

on

default_cannabis_industry_cannamaps

BOCA RATON, Fla., Aug. 12, 2019 (GLOBE NEWSWIRE) — Greenlane Holdings, Inc. (Nasdaq: GNLN) (“Greenlane” or “the Company”), one of the largest global sellers of premium cannabis accessories, CBD and liquid nicotine products, today reported financial results for its second quarter ended June 30, 2019.
Second Quarter 2019 and Other Recent Financial and Operating Highlights:Net sales increased 30.6% to a record $53.0 million;Broadened hemp-derived CBD offerings through exclusive distribution partnerships with leading brands including Bloom Farms, Cookies, Slang Worldwide and Pax Era;Entered partnership with Canopy Growth for exclusive distribution of Storz & Bickel’s vaporizers throughout the U.S.;Added new closed system vaporization products by entering into distribution agreements with Hanu Labs and AVD;Began shipping VIBES Rolling Papers;Net loss was $3.2 million, impacted by $1.7 million of equity-based compensation, $0.3 million of costs associated with transitioning to a public company;Adjusted net loss was $1.2 million compared to adjusted net income of $0.6 million in the prior year period;Adjusted EBITDA was a loss of $1.2 million compared to a gain of $1.1 million in the prior year period;Completed initial public offering (IPO) of 5.25 million primary shares in April 2019; as of July 12, Greenlane Holdings Inc. had approximately 41.9 million Class A shares outstanding on an as converted basis1;Ended the quarter in a strong financial position, with $69.3 million of cash as of June 30, 2019, compared to $7.3 million as of December 31, 2018.1 Reflects the number of shares of Greenlane’s Class A common stock that would be outstanding assuming the exchange of all outstanding shares of Class B common stock and Class C common stock upon redemption of Common Units.All growth rates reflect year over year growth comparing the second quarter of 2019 to the second quarter of 2018.“We generated record second quarter net sales, resulting in over 30% year-over-year growth. We saw growth across multiple product categories in both the U.S. and Canada for the quarter,” stated Aaron LoCascio, Greenlane’s Chairman and Chief Executive Officer. “Sales of JUUL increased nearly 70% over the prior year, led by strong gains in Canada along with continued growth in the U.S. We are working closely with JUUL to support the mission of helping adult smokers to make the switch from combustible cigarettes and executed successful promotions and support for lower nicotine products to build share in the e-cigarette category. We signed several new distribution agreements during the quarter, and we have seen strong initial sales resulting from of our recent entry into the large and growing hemp-derived CBD category. We see considerable opportunities for future growth across the cannabis accessories, CBD and liquid nicotine markets and continue to invest in the people and infrastructure to support long-term growth of each of these categories to drive shareholder value. We ended the quarter in a strong financial position with $69 million of cash, providing ample capital to accelerate our growth through potential future acquisitions.”Second Quarter 2019 ResultsFor the second quarter ended June 30, 2019, the Company reported net sales of $53.0 million, an increase of 30.6%, compared to $40.6 million in the second quarter of 2018. The increase was driven by continued growth of the North American cannabis, CBD and liquid nicotine markets. The increase for the quarter compared to the prior year period included an increase of $10.5 million from sales of e-cigarette products, an increase of $0.8 million from sales of child-resistant storage solution products and $1.8 million from sales of the introduction of new product lines, including hemp-derived CBD products.Gross profit for the second quarter of 2019 was $9.2 million, or 17.3% of revenue, compared to $8.4 million, or 20.7% of revenue, for the same period in 2018. The decline in gross profit as a percentage of net sales on a year-over-year basis primarily reflects changes in sales mix and promotions with a key product supplier.Salaries, benefits and payroll tax expenses for the second quarter of 2019 increased approximately $3.4 million to $7.0 million, or 13.3% of net sales, compared to $3.6 million, or 8.9% of revenue, for the same period in 2018. The increase primarily reflects an increase in personnel expenses resulting from the addition of 65 employees as we continued to expand the Company’s domestic sales and marketing efforts and $1.7 million of equity-based compensation expense.General and administrative (G&A) expense for the second quarter of 2019 increased approximately $1.3 million to $5.4 million, or 10.2% of net sales, compared to $4.1 million, or 10.1% of revenue, for the same period in 2018. The increase primarily reflects an increase in marketing expenses, subcontracted services, executive search and recruitment expenses, new facility expenses and the acquisition of the Company’s headquarters building, the acquisition of Pollen Gear and an increase among other expenses. Additionally, G&A includes $0.3 million of incremental audit and legal fees and consulting expenses related to the Company’s transition to becoming a public company.Net loss for the second quarter of 2019 was $3.2 million and was impacted by $1.7 million of equity-based compensation expense and $0.3 million of non-recurring costs associated with transitioning to a public company.Adjusted net loss for the second quarter of 2019 was $1.2 million compared to adjusted net income of $0.6 million in the second quarter of 2018. Adjusted net loss for the second quarter of 2019 excludes the above-mentioned expenses in net loss. Adjusted net income for the second quarter of 2018 excludes $0.4 million of costs associated with transitioning to a public company.Adjusted EBITDA was a loss of $1.2 million for the second quarter of 2019, compared to a gain of $1.1 million for the comparable period in 2018.Balance Sheet & LiquidityThe Company’s cash at June 30, 2019 was $69.3 million and total debt was $8.3 million, compared to $7.3 million and $48.5 million, respectively, at December 31, 2018. On April 23, 2019, the Company completed an initial public offering of 6.0 million shares, of which 5.25 million shares were offered by the Company raising net proceeds of approximately $80.4 million.Conference Call InformationThe Company will host an investor conference call today at 5:00 p.m. Eastern Time. Investors interested in participating in the live call can dial +1 (877) 705-6003 from the U.S. or international callers can dial +1 (201) 493-6725. A telephone replay will be available approximately two hours after the call concludes and will be available through Monday, August 19, 2019, by dialing (844) 512-2921 from the U.S. or +1 (412) 317-6671 from international locations, and entering confirmation code 13693197.There will also be a simultaneous, live webcast available on the Greenlane Investors website in the Events & Presentations section at https://investor.gnln.com/events-and-presentations or directly at http://public.viavid.com/index.php?id=135640. The webcast will be archived for approximately 30 days.Presentation of Financial Information Use of Non-GAAP Financial Measures The presentation of these financial measures is not intended to be considered in isolation or as a substitute for, or superior to, financial information prepared and presented in accordance with GAAP. Investors are cautioned that there are material limitations associated with the use of non-GAAP financial measures as an analytical tool. These measures may be different from non-GAAP financial measures used by other companies, limiting their usefulness for comparison purposes.Greenlane discloses Adjusted Net (Loss) Income and Adjusted EBITDA, which are non-GAAP performance measures, because management believes these metrics assist investors and analysts in assessing the Company’s overall operating performance and evaluating how well Greenlane is executing its business strategies. You should not consider Adjusted Net (Loss) Income or Adjusted EBITDA as alternatives to net (loss) income determined in accordance with U.S. GAAP as indicators of Greenlane’s operating performance.For more information on Greenlane’s non-GAAP financial measures and a reconciliation of GAAP to non-GAAP measures, please see the “Reconciliation of GAAP to Non-GAAP Results” table in this press release.Forward Looking StatementsCertain matters within this press release are discussed using forward-looking language as specified in the Private Securities Litigation Reform Act of 1995, and, as such, may involve known and unknown risks, uncertainties and other factors that may cause the actual results or performance to differ from those projected in the forward-looking statement. These forward-looking statements include, among others: comments relating to the current and future performance of the Company’s business; growth in demand for the Company’s products; growth in the market for cannabis, nicotine and hemp-derived CBD products; the Company’s marketing and commercialization efforts the Company’s; and the Company’s financial outlook and expectations. For a description of factors that may cause the Company’s actual results or performance to differ from its forward-looking statements, please review the information under the heading “Risk Factors” included in the final prospectus relating to the Company’s initial public offering filed pursuant to Rule 424(b) of the Securities Act of 1933, as amended, which was filed with the SEC on April 22, 2019 and is accessible on the SEC’s website at www.sec.gov.About Greenlane Holdings, Inc.Greenlane (NASDAQ: GNLN) is one of the world’s largest sellers of premium cannabis accessories, CBD and liquid nicotine products. The Company operates as a powerful house of brands, third party brand accelerator and distribution platform for consumption devices and lifestyle brands serving the global cannabis, CBD, and liquid nicotine markets with an expansive customer base of more than 11,000 retail locations, including licensed cannabis dispensaries, and smoke and vape shops. Greenlane has an established track record of partnering with brands through all stages of product lifecycle, providing a range of services including product development, go-to-market strategy, sales and marketing support, market research, customer service, direct-to-consumer fulfillment, warranty repair, supply chain management, and distribution. In addition to owning and operating its own brands, Greenlane is the partner of choice for many of the industry’s leading players including PAX Labs, (Canopy-owned) Storz & Bickel, JUUL, Grenco Science, Firefly, DaVinci, Select, Sherbinski, Bloom Farms, Mary’s Nutritionals, Cookies and dozens of others. Greenlane’s house of brands is comprised of child-resistant packaging innovator Pollen Gear; VIBES rolling papers; the Marley Natural accessory line; the Keith Haring accessory line, Aerospaced & Groove grinders, and Higher Standards, which is both an upscale product line and an innovative retail experience with flagship stores at New York City’s famed Chelsea Market and Atlanta’s Ponce City Market. The Company also owns and operates Vapor.com, an industry leading e-commerce platform which offers convenient, flexible shopping solutions directly to consumers. For additional information, please visit: https://gnln.com/.Media Contact:
Cory Ziskind
ICR
646-277-1232
greenlane@icrinc.com
Investor Contact:
Scott Van Winkle
ICR
617-956-6736
scott.vanwinkle@icrinc.com

          RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES

Original story can be found at: http://www.globenewswire.com/news-release/2019/08/12/1900737/0/en/Greenlane-Announces-Financial-Results-for-the-Second-Quarter-of-2019.html?f=22&fvtc=5&fvtv=41223728

Continue Reading

Industry News

500 Patients in 100 Days and Investing in Australian Companies: Compass Lifestyle Clinics Looks towards the future of Medicinal Cannabis

Avatar

Published

on

default_cannabis_industry_cannamaps

SYDNEY, Australia, Aug. 27, 2019 (GLOBE NEWSWIRE) — Today, Starbuds International (“the Company”), parent company to Compass Lifestyle clinics (“Compass”), is pleased to provide an update on its activities since launching its first medical clinic in Sydney Australia in May.
500 patients in 100 daysWithin 100 days of opening, Compass Lifestyle Clinics has seen over 500 patients and helped provide safe access to medicinal cannabis under the watch of the Therapeutic Goods Association (“TGA”). The company is now looking to expand its capacity to serve patients across Australia.Dr. Teresa Towpik wins Doctor of the YearAt the 2019 Cannabis Industry Awards for Australia, the honours of Doctor of the Year were taken home by Compass Chief Medical Officer, Dr. Teresa Towpik. The award comes as further validation for the work Dr. Towpik has done to bring cannabis into the mainstream as a medicinal cannabis advocate in addition to her tireless work both educating doctors around prescribing as well as serving patients.Investment in Australian Cannabis Grower Medigrowth AustraliaThe Company has also secured a minority investment in Australian Medicinal cannabis late stage applicant and cultivation company Medigrowth Australia. The investment further strengthens Compass’ position in the supply chain, combining patient-centric advocacy & GP education with a leading Australian medicinal cannabis grower and extractor.
             
“Our strategic partnership with Compass consolidates our commitment to patient access and advocacy. We look forward to working with the highly respected team at Compass to educate, inspire and innovate.” says Adam Guskich, Co founder of Medigrowth Australia. “Our combined resources will prove instrumental in providing access to pure, safe, trusted and affordable Australian grown pharma grade medicinal cannabis for Australian patients.”
Along with this announcement, Brianna Martyn, Co-Founder of Starbuds International, has been appointed to the Strategic Advisory Board“Australia has welcomed us with open arms”, says Dave Martyn, President of Compass. “When we did our research, we could see Australians were underserved when it came to safe access to medicinal cannabis. At the same time, from an economic standpoint, we’ve seen what an incredible job creator the cannabis sector has been in Canada. We’ve been fortunate to partner with some of the top cannabis leaders in Australia to play a part in ensuring safe patient access while also helping to grow the industry at large.”The news at a time when medical cannabis acceptance is rapidly growing. With monthly approvals increasing recent news around the removal of red tape surrounding cannabis companies, Compass is poised to expand it’s presence in Australia as it looks towards multi-clinic expansion as well as further investment opportunities.   Those interested in learning more about Compass Lifestyle Clinics can do so at https://compassclinics.com.au or in Canada at https://compasscannabis.ca.About Compass Cannabis ClinicsCompass Cannabis Clinic is a medical cannabis service provider whose core business is focused on providing educational and consultative services to those looking for access to medicinal cannabis. Compass works with a number of Licenced Producers to ensure the right product for the patient while eliminating product bias for prescribers. With several clinics operating in Canada and over 13,000 patients served, Compass has now expanded into Australia with its first clinic in Sydney. Compass Lifestyle Clinics, located in Sydney, with plans for rapid expansion. Compass also operates recreationally in Canada as Starbuds Canada.For further information contactDaniel Winer
Marketing Director
daniel.winer@compassclinics.com.au 
CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION
This news release contains certain forward-looking statements and forward-looking information (collectively referred to herein as “forward-looking statements”) within the meaning of applicable Canadian securities laws. All statements other than statements of present or historical fact are forward-looking statements. Forward-looking statements are often, but not always, identified by the use of words such as “anticipate”, “achieve”, “could”, “believe”, “plan”, “intend”, “objective”, “continuous”, “ongoing”, “estimate”, “outlook”, “expect”, “may”, “will”, “project”, “should” or similar words, including negatives thereof, suggesting future outcomes. Management of the Company believes the expectations reflected in such forward-looking statements are reasonable as of the date hereof but no assurance can be given that these expectations will prove to be correct and such forward-looking statements should not be unduly relied upon. Various material factors and assumptions are typically applied in drawing conclusions or making the forecasts or projections set out in forward-looking statements. Those material factors and assumptions are based on information currently available to the Company, including data from publicly available governmental sources as well as from market research and industry analysis and on assumptions based on data and knowledge of the retail cannabis industry which the Company believes to be reasonable. However, although generally indicative of relative market positions, market shares and performance characteristics, such data is inherently imprecise. While the Company is not aware of any misstatement regarding any industry or government data presented herein, the retail cannabis industry involves risks and uncertainties and is subject to change based on various factors.
Forward-looking statements are not a guarantee of future performance and are subject to and involve a number of known and unknown risks and uncertainties, many of which are beyond the control of the Company, which may cause the Company’s actual performance and results to differ materially from any projections of future performance or results expressed or implied by such forward-looking statements.Any forward-looking statements are made as of the date hereof and, except as required by law, the Company assumes no obligation to publicly update or revise such statements to reflect new information, subsequent or otherwise.A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/e52045f5-e820-43b1-9d91-9f5d3e5e9622

Original story can be found at: http://www.globenewswire.com/news-release/2019/08/27/1907468/0/en/500-Patients-in-100-Days-and-Investing-in-Australian-Companies-Compass-Lifestyle-Clinics-Looks-towards-the-future-of-Medicinal-Cannabis.html?f=22&fvtc=5&fvtv=41223728

Continue Reading

Industry News

Radient Technologies Inc. Releases First Quarter 2020 Financial Results and Provides Corporate Update

Avatar

Published

on

default_cannabis_industry_cannamaps

EDMONTON, Alberta, Aug. 27, 2019 (GLOBE NEWSWIRE) — Radient Technologies Inc. (“Radient” or the “Company”) (TSX Venture: RTI; OTCQX: RDDTF), a global innovator in the industrial scale extraction and downstream processing of premium grade cannabis and hemp derivatives, has released its financial results for the first quarter of its fiscal year 2020, ending June 30, 2019. The financial statements and Management’s Discussion & Analysis are available under the Company’s profile at www.SEDAR.com.
Financial Highlights:Strong cash position:As at June 30th, 2019 the Company had maintained a cash position of CAD $23.5 million.Large inventory for increased future revenue generation:As part of the Company’s business model, which will allow it to benefit from advantages related to cost, scale, and yield provided by its proprietary extraction and processing platform, Radient has secured a large inventory of cannabis biomass (valued at CAD $21.7 million), which will be processed at its Edmonton I manufacturing facility into extracts for sale to Canadian Licensed Producers. This inventory is mainly the result of Radient’s purchase of CAD $19.5 million worth of dried cannabis biomass from Canadian Licensed Producers, including Aurora Cannabis Inc. (“Aurora”), which the Company initially announced on July 8, 2019.
 
Radient has secured buyers for the majority of these extracts. Revenues earned from the sale of these extracts are expected to be in excess of the value of the current total inventory of dried cannabis biomass (CAD $21.7 million), and the Company expects this will have a meaningful positive impact on its earnings reported across fiscal Q2 2020 and/or fiscal Q3 2020. Due to various supply chain factors including shipment of biomass, product analysis and delivery of final product, the Company expects the majority of this revenue will be reported in fiscal Q3 2020.
Corporate Update:Successful scale up of throughput at Edmonton I facility:Since the commencement of extraction and processing activities at its Edmonton I facility (“Edmonton I”) in March 2019, Radient has begun to significantly scale up throughput batch sizes of cannabis biomass by multiples of 5x – 10x, in line with the Company’s expectations. Edmonton I has a throughput capacity of 56,0000 kg/ year of cannabis at full capacity.Recovery and quality of cannabinoids has exceeded expectations:Radient is pleased to report results from the scale-up at Edmonton I have proven:Cannabinoid recovery (yield) from biomass is consistently above 90%, and up to 99%.Cannabis extracts have maintained product stability, including negligible cannabinoid degradation.  Hemp processing line on track for completion:Radient’s Edmonton II Facility (“Edmonton II”), dedicated to the extraction and downstream processing of CBD from hemp, is on track for completion at the end of calendar 2019. Upon completion, Edmonton II is expected to have an annual throughput capacity of 420,000 kg/ year of hemp.Expansion into Germany:Radient’s Germany facility (‘Germany”) is expected to begin initial commissioning in the second half of calendar 2020, scaling up to its full capacity of 280,000 kg of cannabis and 2.8 million kg/ year of hemp thereafter. Please refer to the subsection titled “Germany” under “Cannabis Activities” in the MD&A for further details.Expanded throughput capacity in Canada:Radient’s Edmonton III facility (“Edmonton III”), currently under construction, is expected to be commissioned in the second half of calendar 2020, scaling up to its full capacity of 280,000 kg of cannabis and 2.8 million kg/ year of hemp thereafter.
 
Upon completion of its Edmonton II, Edmonton III and Germany facilities, Radient will have a combined total annual throughput capacity of more than 600,000 kg/year of cannabis and more than 6 million kg/ year of hemp across Canada and Germany.EU GMP compliance:Radient is building both its Edmonton III and Germany facilities to be EU GMP compliant.Post-Reporting:Improved working capital via Amended Loan Facility Agreement:The Company announced the amendment of its original loan facility with Moskowitz Capital Mortgage Fund on August 26, 2019, which increased the amount of the loan from CAD $5.5 million to $8.5 million, and extended the maturity date of the loan from November 1, 2020 to November 1, 2021.Consumer product manufacturing:In anticipation of upcoming changes to the Cannabis Act, which will make the production and sale of edible cannabis, cannabis extracts and cannabis topicals legal in Canada as of October 2019, Radient has been developing a range of compounds and formulations to meet anticipated demand of its clients. In particular, Radient has been focusing on formulation development for various vaping products, edible cannabis products, cannabis extracts and cannabis topicals that its clients will be introducing into the Canadian marketplace. The Company has developed vaping liquid formulations for commercialization and is preparing its manufacturing operations for the production of vaping liquids and cartridge filling, and expects the production of vaping liquid will begin in fiscal Q3 2020. Management Commentary:“This is a key inflection point for Radient,” Denis Taschuk, President & CEO of Radient commented. “During fiscal Q1 2020 we proved our processing and manufacturing capabilities with respect to cannabis, and subsequently acquired a large inventory of cannabis biomass in order to develop white label cannabinoid derivatives for sale to Canadian LPs. We see this as a significant turning point for Radient as a revenue generating company, and we expect this will be clearly reflected in our Q2 2020 and/ or Q3 2020 financials.”  About Radient 
Radient Technologies provides industrial-scale manufacturing solutions for premium natural ingredients and products. Utilizing its patented MAP™ extraction technology, Radient delivers superior customer outcomes in terms of ingredient purity, yield, and cost, serving global market leaders in industries such as foods & beverages, nutraceuticals, pharmaceuticals, cosmetics, and personal care. Since 2016, Radient has expanded its offerings to enter the cannabinoids market, using its proprietary platform to provide premium ingredients including those that contain a broad range of cannabinoid and terpene profiles. Please visit www.radientinc.com for more information.
SOURCE: Radient Technologies Inc.Investors please contact: William (Bill) Wasson, Senior VP of Capital Markets and Investor Relations: wwasson@radientinc.comMedia/press please contact: Caitlin Cheadle, Director of Communications: ccheadle@radientinc.comForward Looking Information:
This press release contains “forward-looking information” within the meaning of applicable Canadian securities legislation. Forward-looking information includes, without limitation, statements regarding the growth of the Company’s business operations; the construction of the Company’s facilities; the Company’s future revenues and timing of such revenues; the Company’s future products; the Company’s ability to sell its products and attract new customers; the expected throughput capacities at its facilities as set out in the “Corporate Update” section above;  the future recovery and quality of the Company’s extracts; the Company’s ability to expand its business internationally; the Company’s ability to grow its business in the cannabis sector and the Company’s future plans. Generally, forward-looking information can be identified by the use of forward-looking terminology such as “plans”, “expects” or “does not expect”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will be taken”, “occur” or “be achieved”. Forward-looking information is subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of Radient, as the case may be, to be materially different from those expressed or implied by such forward-looking information. Although Radient has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking information. Radient does not undertake to update any forward-looking information, except in accordance with applicable securities laws.
NEITHER THE TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Original story can be found at: http://www.globenewswire.com/news-release/2019/08/27/1907438/0/en/Radient-Technologies-Inc-Releases-First-Quarter-2020-Financial-Results-and-Provides-Corporate-Update.html?f=22&fvtc=5&fvtv=41223728

Continue Reading

Industry News

Cannabis World Congress & Business Exposition Brings Industry’s Top Conference Program to Los Angeles

Avatar

Published

on

default_cannabis_industry_cannamaps

NEW YORK, Aug. 27, 2019 (GLOBE NEWSWIRE) — via CannabisNewsWire – Leading Edge Expositions, a company specializing in B2B trade show production, is proud to announce further details of the upcoming Cannabis World Congress & Business Exposition (CWCBExpo) in Los Angeles, California. It will run from September 26 – 28, 2019, at the Los Angeles Convention Center.
The expo has garnered a number of high-powered sponsors. Their diamond sponsor, Freed, is a prominent CBD company known for promoting healthy living. Other big sponsors include Marcum LLP, an accounting group; Zuber Lawler, a global law firm; and CCELL, known for its disruptive vaping technology. These and other leading companies in the cannabis space have come together to help make CWCBExpo a highly valuable and memorable occasion.Event organizers have also ensured the conference schedule will be packed with interesting and informative speeches, workshops and networking opportunities for all guests in attendance. The keynote address, scheduled for September 26, will be given by Steve White, CEO of Harvest, Inc. He will discuss social justice in the cannabis industry.Other speeches on the agenda will cover the cannabis industry from a myriad of angles, including the medical field, business, law and growers. For those interested in business and law, there will be additional workshops detailing how to manage the blossoming cannabis industry and what laws and regulations business owners should be aware of while their businesses grow.Finally, to provide greater ROI to every guest, speaker and sponsor attending, the expo will include multiple networking events designed to foster new business relationships to capitalize on the fast-growing market. On the evenings of September 26 and 27, CWCBExpo will offer networking opportunities for guests to unwind while making useful connections. Attendees are also encouraged to get involved in the various workshops to make important connections.Demand for CWCBExpo is sure to grow even further as the event draws closer. Attendees who purchase their tickets now will benefit from discounted pricing. To register for the upcoming Cannabis World Congress & Business Expo in Los Angeles, visit: https://www.cwcbexpo.com/attend-registration-los-angeles/About Cannabis World Congress & Business Expositions (CWCBExpo)
CWCBExpos are the premier business-to-business events for the legalized cannabis industry and are held 3 times per year in the largest financial, business, and media markets—New York, Los Angeles and Boston. Connect on Twitter, Facebook, Instagram, and LinkedIn: @cwcbexpo.
General Inquiries:
Leading Edge Expositions, LLC
Paramus, New Jersey
201.580.2050 Office
Media Contact:
CannabisNewsWire (CNW) 
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
editor@CannabisNewsWire.com

Original story can be found at: http://www.globenewswire.com/news-release/2019/08/27/1907192/0/en/Cannabis-World-Congress-Business-Exposition-Brings-Industry-s-Top-Conference-Program-to-Los-Angeles.html?f=22&fvtc=5&fvtv=41223728

Continue Reading

Trending